法匹拉韦在COVID-19患者中的药代动力学特征
这项前瞻性观察研究描述了法匹拉韦在成人轻中度COVID-19住院患者中的药代动力学特征,给药方案为负荷剂量3200 mg、维持剂量1200 mg/天共5天,第2天和第4天采血监测。结果显示法匹拉韦浓度变异大且治疗期间显著下降,第2天中位谷浓度21.26 μg/mL,第4天降至1.61 μg/mL,AUC下降68.5%,提示可能需要治疗药物监测。
要点
- 法匹拉韦在COVID-19患者中浓度变异大,治疗期间显著下降
- 第4天较第2天谷浓度中位数由21.26降至1.61 μg/mL,AUC下降68.5%
- 女性患者第2天谷浓度高于男性患者
核心结论
- 法匹拉韦在COVID-19治疗期间浓度变异显著,可能需要治疗药物监测以维持目标浓度。
研究设计与样本
- 前瞻性观察性研究,纳入21例RT-PCR阳性、轻中度COVID-19住院成人患者。
- 法匹拉韦给药5天,负荷剂量3200 mg,维持剂量1200 mg/天,第2天和第4天连续采血。
- 记录患者实验室检查结果及院内死亡率。
主要发现
- 法匹拉韦浓度变异大,治疗期间显著下降。
- 第2天中位谷浓度(C0-trough)为21.26 μg/mL(IQR 8.37-30.78),第4天显著降至1.61 μg/mL(IQR 0.00-6.41)。
- 浓度-时间曲线下面积(AUC)下降68.5%。
- 女性患者第2天C0-trough高于男性患者。
临床怎么用
- 临床使用法匹拉韦治疗COVID-19时,可考虑进行治疗药物监测以维持目标浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID-19 with a positive RT-PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in-hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C0-trough ) on Day 2 was 21.26 (interquartile range [IQR], 8.37-30.78) μg/mL, whereas it decreased significantly to 1.61 (IQR, 0.00-6.41) μg/mL on Day 4, the area under the concentration-time curve decreased by 68.5%. Day 2 C0-trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID-19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.
引用
- Gülhan R, Eryüksel E, Gülçebi İdriz Oğlu M, et al. Pharmacokinetic characterization of favipiravir in patients with COVID-19. Br J Clin Pharmacol. 2022. PMID: 35014080. doi:10.1111/bcp.15227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。